Oxerutins (Venoruton): efficacy in chronic venous insufficiency--a double-blind, randomized, controlled study.
The aim of this study was to confirm the clinical efficacy of oxerutins by evaluation of venous parietal tone and microvascular perfusion in a double-blind, randomized, placebo-controlled study. The study included 60 patients. Venous tone was evaluated by air-plethysmography (APG) in patients with venous insufficiency (CVI). Forty patients were treated with oxerutins and 20 with placebo for 4 weeks. The dose of the first 2 weeks was higher than that of the following 2 weeks. The age range was between 18 and 65 years. Randomized patients received treatment (oxerutins or placebo) according to the grade of CVI. Patients with grade I CVI received 2 g/day in the first 2 weeks of treatment and 1 g/day in the following weeks. Patients with grade II CVI received 3 g/day in the first 2 weeks and 2 g/day in the following 2 weeks. Visits were scheduled at baseline time (visit 1), at 2 weeks (visit 2) and at 4 weeks (visit 3). They were assessed with the following: (1) APG; (2) light reflection rheography (LRR); (3) capillaroscopy; (4) liquid crystals thermography. CVI signs/symptoms--heavy legs, edema, paresthesia, and cramps--were evaluated following a 4-point rating scale (0 = no symptom; 3 = severe symptoms). At visit 3 a final opinion on efficacy was provided by both patients and investigators, based on a 4-point scale (none, fairly good, good, excellent). The two groups were homogeneous for age, sex, and clinical distribution. The changes in venous capacity, were significant (p<0.01) in the oxerutins group at visits 2 and 3; values in the placebo group remained unchanged. The changes in LRR were significant in the treatment group at visits 2 (p<0.05) and 3 (p<0.01); values in the placebo group remained unchanged. Changes in temperature were significant in the oxerutins group at visits 2 (p<0.05) and 3 (p<0.01); changes in the placebo group were not significant at the end of the study. Capillaroscopy showed an improvement in patients treated with oxerutins. The results of the analysis of signs/symptoms favored active treatment. The overall effects of oxerutins were significantly better than the effects of placebo. Considering both noninvasive tests and clinical evaluation, oxerutins is effective in controlling chronic venous hypertension, without side effect, and with good tolerability.
Petruzzellis
Vincenzo
V
Dermatology Department, Di Venere-Giovanni XIII Hospital, Bari-Carbonara, Italy.
Troccoli
Teresa
T
Candiani
Carlo
C
Guarisco
Raffaella
R
Lospalluti
Mario
M
Belcaro
Gianni
G
Dugall
Mark
M
D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use*; D002908:Chronic Disease; D004311:Double-Blind Method; D004487:Edema / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D006801:Humans; D006896:Hydroxyethylrutoside / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D007866:Leg / Q000098:blood supply / Q000473:pathology; D008297:Male; D008833:Microcirculation; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy / Q000503:physiopathology; D010147:Pain Measurement; D010991:Plethysmography / Q000379:methods; D010992:Plethysmography, Impedance; D013817:Thermography; D016896:Treatment Outcome; D014689:Venous Insufficiency / Q000188:drug therapy* / Q000503:physiopathology
D000925:Anticoagulants; D006896:Hydroxyethylrutoside; C005865:troxerutin